Parallax Volatility Advisers
PRTK

Parallax Volatility Advisers’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Parallax Volatility Advisers’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-72,300
Closed -$1.39M – 4345
2017
Q1 		$1.39M Buy
+72,300
New +$1.14M ﹤0.01% 1009

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Parallax Volatility Advisers's PRTK Position: Q4 2018 in Review

Parallax Volatility Advisers sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 7,379 shares — an estimated $72K sold.

Parallax Volatility Advisers first reported a position in PRTK in Q1 2017 and held it in 7 quarters. The position peaked at $579K in Q3 2017. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • Parallax Volatility Advisers reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 7,379 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $72K.
  • Parallax Volatility Advisers first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
  • Parallax Volatility Advisers's Paratek Pharmaceuticals, Inc. position peaked at $579K in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Parallax Volatility Advisers's 13F filing for Q4 2018, filed 14 Feb 2019.